Answers are grounded in this paper and cite their sources.
Oral delivery of small interfering RNA (siRNA) holds great potential for treating gastrointestinal (GI) diseases. However, its therapeutic efficacy is severely constrained by premature nanoparticle destabilization in the harsh GI milieu, inefficient cellular internalization and lysosomal/endosomal entrapment. Herein, we developed hydroxyl-functionalized α-helical polypeptides that harness multivalent interactions to overcome harsh GI environments and enable efficient oral siRNA delivery. Through rigorous screening of a structurally tuned polypeptide library, PVBLG-H7 was identified as the top performing candidate with terminal hydroxyl groups and optimized side-chain length. Benefiting from synergistic electrostatic, hydrophobic, and hydrogen-bonding interactions, PVBLG-H7 tightly encapsulates siRNA and achieves exceptional payload stability. Ultimately, it demonstrates robust siRNA delivery efficacy both in vitro and via oral administration in vivo. Structure−activity relationship analysis further highlights that terminal hydroxyl-mediated hydrogen bonds play a pivotal role in reinforcing complexation stability for efficient oral delivery. Overall, this study establishes a robust hydroxyl-functionalization polypeptide strategy for oral siRNA delivery.
No takes yet. Share an insight, caveat, or question.
Bi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: